Podcasts about copd

In this week's Real Take, Tara Rafter reflects on her mother's final days living with COPD​ and the heartbreak of saying goodbye to the woman who had been her anchor throughout life.​If this excerpt resonates with you, I highly recommend listening to the full episode:Tara Rafter: Hypervigilance to Healing​Growing up in a home impacted by alcoholism and domestic violence, she learned from a young age how to navigate uncertainty. Despite the difficulties her family faced, she speaks with remarkable compassion about both of her parents, who died far too young.A​nd alongside her personal story, Tara brings the perspective of a Master Neuro Linguistic Programming Practitioner and Executive Coach.Listen to the full episode wherever you get your podcasts. Hosted on Acast. See acast.com/privacy for more information.

​Topics covered include:​ Alcoholism​, domestic violence​, hypervigilance​, compassion​, motherhood​, self-abandonment​, being a carer​, death and loss​, grief​, faith​, spirituality​, forgiveness​, love​, safety​, self-worth​, self-sabotage​, overwhelm​, healing​.This week I'm joined by Master Neuro Linguistic Programming Practitioner, Executive Coach and founder of The Navigation Coach, Tara Rafter.Tara lives in Mayo with her husband Kevin and their son Kai.In this deeply honest conversation, Tara shares the story of her childhood growing up in a home impacted by alcoholism and domestic violence. She speaks candidly about the hypervigilance she developed from a young age, the lasting impact those experiences had on her life, and the remarkable compassion she holds for her father despite the challenges her family faced.Tara's story is one of resilience, but also of love, forgiveness and understanding. She reflects on her relationship with both of her parents, who died far too young. Her father passed away at the age of 58, while her beloved mother​, who was her anchor throughout life​, lived with COPD for several years before she died.We also explore motherhood, self-abandonment, self-worth, self-sabotage, overwhelm​ and what it means to truly feel safe in yourself.Alongside the more difficult chapters, this conversation is full of warmth and humour. Tara talks about her love of music​ and heading off to gigs on her own, her deep faith and the practices that have helped her navigate life's challenges.You can connect with Tara here:Website: thenavigationcoach.comEmail: tara@thenavigationcoach.com Hosted on Acast. See acast.com/privacy for more information.

In this episode of the RCP Medicine Podcast, respiratory consultant and clinical lead for environmental sustainability Dr Thom Daniels joins host Dr David Charles to explore why air quality should be treated as a core clinical issue rather than a distant environmental concern. Drawing on landmark coroner's cases, including the deaths of Ella Adoo Kissi Debrah and Awaab Ishak, they examine how outdoor and indoor pollution contribute to asthma, COPD, cardiovascular disease, stroke, dementia and health inequalities across the life course. The discussion covers practical ways to ask about air quality in consultations, from unexplained coughs to secondary prevention clinics, and sets out simple, evidence informed advice clinicians can offer to patients. They also consider policy and global perspectives, racial and social justice dimensions, and how clinicians can support patients who feel fatalistic about the environment.Resources https://www.rcp.ac.uk/policy-and-campaigns/policy-documents/a-breath-of-fresh-air-responding-to-the-health-challenges-of-modern-air-pollution/ https://www.rcp.ac.uk/news-and-media/news-and-opinion/air-pollution-linked-to-30-000-uk-deaths-in-2025-and-costs-the-economy-and-nhs-billions-warns-royal-college-of-physicians/https://www.rcp.ac.uk/media/5r2kmmi4/rcp-full-report-a-breath-of-fresh-air-responding-to-the-health-challenges-of-modern-air-pollution.pdfThe RCP's six-step programme for the new consultant | RCP Explore our CPD portfolio by your career stageEducation and professional developmentLeadership CPDTeach the teacherEducational supervisorSix-step programme RCP Social MediaInstagramLinkedInFacebookBlueskyMusic Ep 50 onward - Bensound.com  Ep 1 - 49 'Impressive Deals' - Nicolai Heidlas Any adverts within this podcast may use computer generated voices

Matthew "Oki" O'Connor is the CEO of Scientific Affairs at Cyclarity Therapeutics, a clinical-stage biotech building a new class of medicines designed not to slow the accumulation of vascular damage but to reverse it. Oki and Chris first crossed paths as postdocs at Lawrence Berkeley National Lab in the mid-2000s — Oki was in Irina Conboy's lab, not far from the late Judy Campisi's group, where Chris was then working on cellular senescence. After Berkeley, Oki spent nearly a decade running the research program at the SENS Research Foundation, the organization most identified with the "damage repair" framing of aging biology, before co-founding Cyclarity (then known as Underdog Pharmaceuticals) in 2019 to translate one of SENS's most drug-tractable ideas into an actual molecule.When Oki was last on the show in March of 2023 (Episode 36), Cyclarity was deep in IND-enabling work and its lead asset, UDP-003, had only ever seen the inside of a mouse artery. At the end of that conversation, Chris asked what Oki hoped to be discussing the next time he visited. He answered, bluntly, that he wanted to be presenting human data. Last month, at the AHA Vascular Discovery Sessions, Cyclarity reported the results of their first-in-human Phase 1 trial of UDP-003 — a designed cyclodextrin that selectively binds 7-ketocholesterol, the oxidized cholesterol species that drives foam cell formation and arterial plaque. He's back to discuss what the drug actually did when it went hunting for 7KC inside a living human being.In this episode, Chris and Oki cover the unmet need that lipid-lowering drugs — statins, PCSK9 inhibitors, the coming Lp(a) agents — still don't address: none of them remove the damage already sitting in an artery wall. Oki explains the basic chemistry of 7-ketocholesterol and why macrophages, lacking the machinery to recycle it, collapse into foam cells and seed the necrotic core of advanced plaque. They walk through the engineering of UDP-003 as a dimeric beta-cyclodextrin "double cone" tuned for a single oxidized cholesterol species, the design of the 72-volunteer Australian Phase 1, and the exploratory pharmacodynamic readout that has the field's attention: dose-dependent urinary excretion of 7KC, stoichiometric with drug, cleared within a day. The conversation then turns to the 150-patient Phase 2 plan in coronary artery disease patients with plaque imaging as the primary biological readout, the funding math that stands between Cyclarity and that trial, the platform's reach into NASH, vascular dementia, AMD, and aging itself, and how all of this descends from the SENS damage-repair philosophy that Oki has been carrying since LBL.The Finer Details:- Why current standard of care is not enough — statins, PCSK9 inhibitors, GLP-1s, and the soon-to-arrive Lp(a) lowering agents all act by slowing the accumulation of arterial damage, not by reversing what's already there; despite 30 years on the market, statins have never demonstrated an all-cause mortality benefit in a clinical trial, and even the best statin imaging data shows only 1–2% plaque volume regression at very high doses in a subset of patients- The scale of the problem — atherosclerosis is estimated to contribute to roughly 40% of all human deaths once heart attack, stroke, and a surprisingly large COPD contribution are risk-adjusted in, on top of an enormous morbidity tail that includes angina, peripheral artery disease (up to and including amputation), and a growing case for vascular dementia as an undercounted driver of cognitive decline- The biology of 7-ketocholesterol — when an oxygen free radical reacts with cholesterol, it preferentially attacks the 7 position, and a second oxidation step locks the molecule into 7KC, a stable toxic species cells were essentially never equipped to recycle; it builds up in long-lived cells like macrophages, eventually shutting down their ability to traffic lipids back to the liver via HDL and converting them into foam cells that seed soft plaque and, over years, the necrotic core of advanced lesions- The molecular design of UDP-003 — cyclodextrins are naturally occurring carbohydrate rings; the beta size fits half a cholesterol molecule, and Cyclarity's in silico work showed that two beta-cyclodextrins facing wide-side to wide-side form a "double cone" that can fully encapsulate a single cholesterol; engineered correctly, that wrapper can be made selective for 7KC over native membrane cholesterol, which is what gives the drug its therapeutic window- The Phase 1 trial design and result — a traditional 72-volunteer safety study in Australia, split between single ascending dose and multiple ascending dose arms, escalating up to six doses at what Cyclarity believes will be the efficacious level; no serious adverse events, no bioaccumulation, drug excreted essentially completely in the urine (as predicted preclinically), and — the headline exploratory endpoint — dose-dependent urinary 7-ketocholesterol appearing on the same timescale as the drug, consistent with one molecule of UDP-003 binding one molecule of 7KC and leaving the body together- What the urinary 7KC readout can and cannot tell you — the easiest 7KC to mobilize is the free pool in circulation, but there is not nearly enough of it floating in the bloodstream to account for what came out in urine, which means the drug is reaching deeper compartments; how much is coming from vessel wall plaque versus liver versus other peripheral tissues will require the imaging endpoints of Phase 2 to answer- The Phase 2 plan — 150 coronary artery disease patients (the coronary being, as Oki puts it, the artery most likely to kill you), with baseline plaque imaging, a year of dosing, and a repeat scan; safety and PK continue, inflammatory biomarkers come on, and plaque volume change is the prize — for context, a 1% change in plaque volume is associated with roughly a 20% change in next-year risk of heart attack or stroke- The funding math and the platform — Cyclarity has raised $33M to date and needs roughly $45M more to run the Phase 2, with Phase 3 cardiovascular outcomes trials running into the hundreds of millions and likely requiring a pharma partner; beyond atherosclerosis, 7KC is elevated in NASH livers, in Alzheimer's brains, and in the retinal cells that die in age-related macular degeneration, and the underlying chemistry — designed binders that drag a specific toxic molecule out of the body — is meant to generalize into a pipeline against other accumulated damage species, the direct intellectual descendant of the SENS damage-repair programQuotes:"Atherosclerosis, or the plaque that builds up in your blood vessels in your arteries, is estimated to cause approximately 40% of all human death.""When [the macrophage] eats up too much oxidized cholesterol, it just accumulates it… And that's when you get this transition to these kind of monster blob cells called foam cells.""One molecule of our drug is supposed to bind one molecule of 7-ketocholesterol and then go away and never be seen again. You excrete both of them together.""A 1% change in plaque volume is associated with a 20% risk in the next year of your probability of having a heart attack or a stroke.""You pick one target at a time, you do it well, and you take it all the way to the clinic and hopefully prove that you can actually cure patients, help them get better, help their plaque shrink away, and prove that this approach can work."Links:Cyclarity Therapeutics: https://cyclarity.com

Welcome to the Atomic Anesthesia podcast hosted by CRNA professor Dr. Rhea Temmermand and Co-Founder Sachi Lord. On this show, you'll hear clear, clinically grounded discussions designed for nurse anesthesia residents and CRNAs who want to feel more confident in complex pharmacology, physiology, and real-world anesthesia decision-making.Want more content like this? Become a member of our learning platform: http://atomicanesthesia.comIn this episode:Why COPD is more than a lung problem — how alveolar destruction, V/Q mismatch, and cor pulmonale connect at the bedsideHow to ventilate a COPD patient intraoperatively: I:E ratios, PEEP strategy, and avoiding auto-PEEPThe pharmacology of bronchodilators — LABAs, LAMAs, and inhaled corticosteroids — and which ones to continue on the day of surgeryAnesthetic agent selection for reactive airways: why volatile agents help, why nitrous oxide doesn't, and when to consider TIVAPostoperative priorities: extubation to NIV, oxygen titration in CO2 retainers, and preventing reintubation

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EQG865. CME/MOC/AAPA credit will be available until June 17, 2027.Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EQG865. CME/MOC/AAPA credit will be available until June 17, 2027.Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

Discover how to tap into your body's ultimate internal repair system and unlock the hidden regenerative power of your own stem cells.In this episode of Modern Healthspan, we explore the extraordinary capability of the human body to heal itself from within. Stem cell scientist Christian Drapeau breaks down how our bone marrow acts as a continuous engine for cellular renewal, deploying stem cells to target, repair, and revitalize damaged tissues. While our natural baseline release shifts over time, groundbreaking clinical data reveals that we can actively encourage our body to release fresh waves of its own stem cells into circulation. We discuss a remarkable six-month human trial where daily stem cell mobilization successfully helped restore normal heart function in chronic heart failure patients. You will also learn practical protocols to optimize this internal repair system using fasting, blood flow support, and advanced recovery tools like PEMF to guide these powerful cells exactly where your body needs them most.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EQG865. CME/MOC/AAPA credit will be available until June 17, 2027.Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EQG865. CME/MOC/AAPA credit will be available until June 17, 2027.Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

Policeman To Face Murder For Tear-gassing Resident To Death In Edohttps://osazuwaakonedo.news/policeman-to-face-murder-for-tear-gassing-resident-to-death-in-edo/#Amnesty #Benin #Children #Ebojele #Edo #keke #Okpebholo #Police #UNBarely 48 hours after a serving police officer on May 25, 2026 at Uwelu area of Ogida quarters in Benin City tear-gas a resident to death, Matthew Akubo, a tricycle rider who is also said to be an ex police officer of an elderly age, a more devastating tragedy was apparently averted on May 27, 2026 at the Samuel Ogbemudia Stadium during the 2026 Children's Day Celebration when some security operatives used pepper spray on school children who came for the celebration, an action capable of causing death but the Chief Medical Director, Edo Specialist Hospital, Dr Anthonia Njoku denied and dismissed the claims that about 5 children died as a result of the incident, and the Edo Command of the Nigeria Police Force in a press statement failed to state if there was any death casualty or not, but stated that 4 persons including the seller of the pepper spray chemical substance have been arrested and detained  in connection with the Children's Day incident, adding that, the policeman who caused the death of the tricycle rider has been in detention waiting to be arraigned for possible act of murder, this, our research study shows that the less lethal weapon of chemical substances like tear-gas and pepper spray may be seen as an act of deliberate murder or attempted murder if used on a closed range, enclosed enviroenment like hall; big or small because the chemical substances from our assessment are meant only to be used on a long range open air outdoor spaces where people have alternatives means to run and leave the contaminated areas and inline with global standard on the use of the chemical substances, tear gas is never meant to be used on vulnerable populations or individuals with medical conditions, as international bodies like the United Nations Office of the High Commissioner for Human Rights, OHCHR and health organizations warn it can cause permanent injury, severe complications, or death, in addition, the chemical causes instant airway constriction that can trigger fatal respiratory failure in people with asthma or COPD—a severe risk that prompted the American Thoracic Society, ATS to call for a total moratorium on its use, because, simultaneously, the intense physical stress can induce cardiac arrest in those with heart disease, as documented by Physicians for Human Rights, PHR, and according to strict deployment standards from Amnesty International, infants and young children face significantly higher risks because their developing lungs breathe faster, and heavy gas vapors settle near the ground, pregnant individuals face severe risks of premature labor or miscarriage, a danger highlighted in field reports by National Nurses United and reproductive toxicology data published by the National Institutes of Health, NIH, also, the elderly suffer prolonged tissue damage due to a reduced physical ability to flee, and finally, the American Lung Association warns that people with eye conditions—especially contact lens wearers—can suffer chemical burns and permanent vision loss from trapped toxins, though legally, while the Chemical Weapons Convention, CWC permits domestic law enforcement usage, the UN Guidance on Less-Lethal Weapons explicitly dictates that police operations must give special consideration to these protected groups to avoid unlawful, disproportionate force. #OsazuwaAkonedoBecome a supporter of this podcast: https://www.spreaker.com/podcast/osazuwaakonedo--4980924/support.Kindly support us for more productivity and efficiency in news delivery.Visit our donation page: DonateYou can also use our Mobile app for more news in different formats: CLICK TO DOWNDLOAD ON GOOGLE PLAY STORE 

Christina Prevett shares a detailed case study of a COPD patient named Bob, demonstrating how HIIT training can improve functional capacity and oxygen efficiency in pulmonary rehabilitation. The discussion covers personalized exercise protocols, monitoring strategies, and the importance of adaptable training for chronic conditions.  

On this episode of Healthline 3, Nate Blanchard sits down with Dr. Jerry San Pedro to discuss how summer heat and humidity impact your lungs and overall health. From asthma and COPD to air quality and exercise, they break down why breathing gets harder in the heat—and what you can do about it.Plus, viewer call-ins cover real concerns about managing symptoms, staying hydrated, and knowing when to seek medical help.

In this week's episode of the Xtalks Life Science Podcast, host Vera Kovacevic, Editor-in-Chief at Xtalks, spoke with Diego Ardigò, Executive Vice President, Global R&D at Chiesi, a biopharma company focused on respiratory health, rare diseases and specialty care. Respiratory medicine presents unique drug development challenges because successful therapies depend not only on the drug itself, but also on the formulation and delivery device. As innovation continues across asthma and chronic obstructive pulmonary disease (COPD), developers must balance performance, usability, sustainability and continuity of care. In this episode, Diego discusses how Chiesi approaches innovation in respiratory disease drug development and why developing inhaled therapies requires careful integration of drug formulation, device design and patient experience. The conversation also explores the growing focus on sustainability in respiratory care. Diego discusses how the industry can transition toward more environmentally sustainable inhaler options while maintaining treatment continuity for patients who are stable on their current therapies. In addition, Diego discusses the role of inhaler technique, patient behavior and long-term treatment adherence in shaping R&D decisions. Diego also explains why respiratory medicine offers valuable lessons for the broader pharmaceutical industry in balancing innovation, sustainability and patient-centered care. Tune in to learn more about the future of asthma and COPD drug development and how respiratory medicine is evolving to meet both patient and sustainability goals. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

What does it take to go from helping millions of people breathe easier to helping patients keep their legs?   Join The Heart of Innovation as Kym McNicholas talks with Sarvajna Dwivedi, Ph.D., entrepreneur, inventor, and CEO of AngioSafe, whose career has spanned some of the most challenging problems in medicine.   Sarvajna co-founded Pearl Therapeutics, a company focused on breakthrough respiratory therapies that was ultimately acquired by AstraZeneca for $1.15 billion. Along the way, he helped develop inhaled therapies and drug-device combinations designed to improve the lives of patients with asthma and COPD. (AngioSafe United States)   Today, his focus has shifted from the lungs to the arteries.   As CEO and co-founder of AngioSafe, Sarvajna is leading the development of the Santreva-ATK Endovascular Revascularization Catheter, a novel device designed to restore blood flow through some of the most challenging chronic total occlusions (CTOs) physicians encounter in patients with peripheral artery disease (PAD). The technology is designed to cross completely blocked arteries, compress plaque, create a new channel, and restore blood flow without relying on a guidewire or external power source. (Medical Economics)   In this episode, we discuss:   • How a pharmaceutical scientist became a medical device innovator   • The story behind Pearl Therapeutics and its $1.15 billion acquisition   • Why chronic total occlusions remain one of the biggest challenges in PAD treatment   • How AngioSafe's Santreva-ATK technology works   • What it means to restore blood flow through arteries that are 100% blocked   • The future of cardiovascular and vascular innovation   If you or someone you love has peripheral artery disease, diabetes, leg pain while walking, non-healing wounds, or has been told an artery is completely blocked, this is a conversation you won't want to miss.  

We are in the third week of our four-part series on the 5th-largest killer in America.  This week, we talk about the diagnostics that can help prevent Chronic Lower Respiratory Disease and the tests that can help provide a roadmap to actually reverse it.  In this episode, you'll learn:—How Asthma is the majority of CLRD cases, while COPD is the number one category of CLRD deaths.—Why the Spirometry Lung Function Test is the most important tool to diagnose the Lungs.  And why Dr. Prather does not charge for follow-up Spirometry tests for those with severe Lung problems. —What factors Dr. Prather looks for to determine when  a Chest X-Ray is needed or when CT imaging is required for a patient.  And the common calcification Dr. Prather sees on Chest X-Rays due to Indianapolis being the "Histoplasmosis Capitol of America". —The importance of Vitamin D testing for respiratory health and the role it played during COVID.  And why Dr. Prather believes CLRD could be lowered by 85% if people just keep their Vitamin D levels in proper range.—The importance of Vitamin A as the recommended treatment for Measles.  And the history behind Cod Liver Oil as a great supplement for kids.—The importance of a Pulse Oximeter to check Blood Oxygen levels as a standard screening for all patients. —How Hair Analysis has been an important key to the health of so many patients, such as identifying toxic heavy metals like Cadmium which cause long-term damage to the Lungs. —Why Dr. Prather believes Sputum Cultures are under-utilized. —How a Stool Kit plays an important role for Lung health by identifying leaky gut issues that lead to Food Allergies.  Plus, how Parasites are a big cause of severe childhood Asthma and adult-onset Asthma.—Why too LOW levels of Hydrochloric Acid "almost always kicks off allergies" and is the reason for GERD and heartburn.  And why Proton Pump Inhibitors like Pepcid actually make the problem worse by lowering the Hydrochloric Acid in your stomach even more.http://www.TheVoiceOfHealthRadio.com*Receive exclusive bonus content as a member of our Voice Of Health Patreon Community:https://www.patreon.com/cw/VoiceofHealthPodcast

Learn how COPD treatment is changing, including newer medications, ways to prevent flare-ups, affordability tips and questions to ask your pulmonologist. Featuring Dr. Kathryn Robinett, a pulmonary critical care physician at UMMC Midtown Center for Pulmonary Health.  For more information about Dr. Robinett 

Send us Fan MailMorning Prayer (Rejoice in LORD; Body of Christ; Blood Pressure; COPD; Mercy of God) #morningprayer #christianprayer #Jesus #HolySpirit #copd #joy #loveThank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peaceaimingforjesus.comYouTube Channel https://www.youtube.com/@aimingforjesus5346Instagram https://www.instagram.com/aiming_for_jesus/Threads https://www.threads.com/@aiming_for_jesusX https://x.com/AimingForJesusTik Tok https://www.tiktok.com/@aiming.for.jesus

How deep you breathe is the number one indicator of how long you will live.  This week, we continue our four-part series on the 5th-largest killer in America.  In this episode, we talk about:—How the majority of people with Chronic Lower Respiratory Disease have Asthma, which can also lead to COPD.—Why quitting cigarette smoking is the most important treatment for your lungs.  And how Holistic Integration is able to help patients to quit smoking through Auriculotherapy, Acupuncture ,and Homeopathy.—The importance of proper deep, diaphragmatic breathing techniques to keep,your lungs healthy.  And why Dr. Prather believes this is the main reason that women develop Chronic Lower Respiratory Disease more than men. —The reason Dr. Prather says that Structure-Function Care can reverse Lung damage and that at Holistic Integration, "We prove it all the time". —The Diathermy treatment used at Holistic Integration that was originally developed for the lungs to treat Pneumonia.  And how patients say they can breathe again after this treatment, which Dr. Prather calls "our magic lung fixer".—The role of allergies and parasites as underlying causes of Asthma.  And how Holistic Integration treats those issues naturally. —How Indianapolis is known as the Histoplasmosis Capitol of the World, which is a cause of Chronic Lower Respiratory Disease.  Plus, how Histoplasmosis is the leading cause of blindness in Indiana. —The most common viruses that cause Chronic Lower Respiratory Disease.  And how COVID helped contribute to lung damage that may lead to more Chronic Lower Respiratory Disease cases in future years.—How cough suppressants prevent mucus from being removed from the body, which is a breeding ground for germs and bacteria.  And how antibiotics will clear up your symptoms, but leave the infection in place to do further damage because they shut the immune response down. —The Importance of Hyaluronic Acid to "re-inflate your lungs" (and also to make your joints feel better).  And the most effective supplement for lung health that Dr. Prather uses at Holistic Integration. http://www.TheVoiceOfHealthRadio.com*Receive exclusive bonus content as a member of our Voice Of Health Patreon Community:https://www.patreon.com/cw/VoiceofHealthPodcast

Klinisch Relevant ist Dein Wissenspartner für das Gesundheitswesen. Drei mal pro Woche, nämlich dienstags, donnerstags und samstags, versorgen wir Dich mit unserem Podcast und liefern Dir Fachwissen für Deine klinische Praxis. Weitere Infos findest Du unter https://klinisch-relevant.de

Before watching the video, can you guess which conditions vitamin D has actually been proven to work for in randomized, double-blind, placebo-controlled trials?

In aflevering 369 van Wetenschap Op Woensdag duiken Istvan, Mario en Minya diep in onze luchtwegen. Dit keer bespreken we een belangrijk en emotioneel thema dat milieus raakt: COPD en Astma. Wat is nu écht het biologische verschil tussen deze twee? Waarom is een waterpijp of een jointje roken absoluut géén 'gezond' alternatief voor tabak? En wat heeft popcorn in hemelsnaam te maken met een ongeneeslijke longziekte?Wat kun je verwachten?De anatomie van de long: Mario legt haarfijn uit hoe emfeseem en chronische bronchitis je longblaasjes slopen.Vaping & Cannabismythen doorgeprikt: Waarom e-sigaretten en joints minstens zo schadelijk zijn als een gewoon pakje peuken.Historische weetjes: Van de oude Grieken tot het bizarre verhaal van 'Polio Paul' en zijn ijzeren long.Licht aan het einde van de tunnel: Een spectaculaire Nederlandse medische doorbraak met 'mini-longetjes' die in de toekomst longweefsel kan herstellen!

Breathing out shouldn't feel like pushing air through a straw, but for millions of people that's the daily reality of COPD. We sit down and translate chronic obstructive pulmonary disease into plain English, starting with what the name really means and why the main problem is often getting air out, not just getting air in. If you've ever heard someone say they “can't catch their breath,” we give you a clear picture of what may be happening inside the lungs.We walk through a simple model of breathing using an upside-down tree and tiny balloon-like air sacs, then explain what changes in COPD: inflamed, narrowed airways and air sacs that lose their stretch. That combination can trap air, making each new breath feel harder than the last. We also talk about the slow burn of how COPD develops over time, why smoking is the most common cause, and how pollution, occupational dust or chemicals, secondhand smoke, and rare genetic factors can also play a role.From there, we get practical. We cover common COPD symptoms (shortness of breath with activity, chronic cough, mucus, wheezing, fatigue), how spirometry helps diagnose airflow limitation, and what treatment can actually do. We discuss inhalers, pulmonary rehabilitation, oxygen therapy for advanced cases, and why staying up to date on flu, RSV, and COVID vaccines matters for people at higher risk. We also break down COPD exacerbations, the flare-ups often triggered by infections that can cause a step down in lung function, and why early prevention and timely care are so important.Stick around for our post-medicine banter too. If this helped you understand your body a little better, subscribe, share it with someone who needs it, and leave a review so more people can find straightforward health education.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

This week, we begin a four-part series on the 5th-largest killer in America.  In this episode, you'll discover:—How COPD (Chronic Obstructive Pulmonary Disease) is responsible for the overwhelming majority of Chronic Lower Respiratory Disease (or CLRD) deaths.  And how Emphysema and Asthma are also included in this category. —Why Dr. Prather says it is "a major issue" to get patients (and sometimes their doctors) to take their shortness of breath seriously. —The devastating impact of cigarette smoking on CLRD.  And how Dr. Prather has seen young people whose Lungs have shut down even after just three months of vaping.—Why Dr. Prather says that marijuana can actually even be worse than cigarettes on the Lungs.—How Asthma can be a precursor of COPD and damages the Lungs over time.  Plus, the role of obesity in contributing to Lung problems and CLRD. —The influence of nutrition on Lung Disease and why Dr. Prather believes Fiber is the key. —The Alpha-1 antitrypsin generic factor that can be a root cause of Lung disease.  And how infections like Histoplasmosis can increase your risk of developing COPD.—The Spirometry Lung Function Test at Holistic Integration that reveals the health of your Lungs. —How you CAN improve the health of your Lungs and even regenerate your Lungs through Structure-Function Care. —Why Dr. Prather says how deep you breathe is the number one indicator of how long you will live. http://www.TheVoiceOfHealthRadio.com*Receive exclusive bonus content as a member of our Voice Of Health Patreon Community:https://www.patreon.com/cw/VoiceofHealthPodcast

As part of the May issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy Chief Editor Don Sin interviews John Fahy (Division of Pulmonary and Critical Care Medicine, and the Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA) about his state-of-the-art review of the pathobiology and treatment of mucus plugs in asthma and COPD , published in this issue of the ERJ (https://doi.org/10.1183/13993003.02358-2025). Cite this podcast as: ERJ Podcast May 2026: Mucus plugs in asthma and COPD. Eur Respir J 2026; 67: 26E6705 [https://doi.org/10.1183/13993003.E6705-2026].

Guest: Barry Quart, CEO and DirectorCompany: Connect Biopharma, NASDAQ:CNTBWebsite: https://www.connectbiopharma.com/Connect Biopharma Bio:Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect has granted an exclusive license to Simcere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately $110 million upon the achievement of certain development, regulatory and commercial milestones. Connect is also eligible to receive royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China.Barry Quart Bio:Dr. Barry Quart brings over 30 years of extensive experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. He has personally led several early-stage biotech companies through late-stage clinical development, regulatory strategy, highlighted by nine U.S. Food and Drug Administration (FDA) approved drugs.Dr. Quart was most recently CEO at Heron Therapeutics. He first served as CEO and Director starting 2012, transitioned to President and CEO in 2019 and was named Chair of the Board in October 2020. At Heron, Dr. Quart oversaw the development and approval of four drugs: two drugs for CINV (CINVANTI® and SUSTOL®) and two acute care drugs (ZYNRELEF® and APONVIE®). Prior to Heron, Dr. Quart co-founded Ardea Biosciences, Inc. in 2006 and served as its President and Chief Executive Officer and Director from its inception through its acquisition by AstraZeneca PLC in 2012. At Ardea, Dr. Quart invented and oversaw the development of a drug for gout (ZURAMPIC®), as well as the design and development of a series of MEK inhibitors for cancer that were licensed to Bayer AG. Dr. Quart currently serves on the Board of Directors of Kiniksa Pharmaceuticals. He is an inventor on 18 U.S. patents and an author on 75 publications and abstracts. Dr. Quart received his Pharm.D. from the University of California, San Francisco.

Dr. Daphne Bascom earned a DPhil/PhD in physiological sciences at the University of Oxford, a medical degree at the University of Pittsburgh, and completed fellowship training in microvascular and reconstructive surgery of the head and neck at Oregon Health Sciences University. She has more than two decades of executive leadership across health systems, health technology, and community health. Most recently, she served as Vice President of Population Health at Saint Luke’s Health System in Kansas City. So, how and why did she leave all of that to pursue lifestyle medicine, a “vegetable-forward” way of life, and a completely different kind of care? As we've heard from many of our guests, for Dr. Bascom, it was personal. Between witnessing her mother's long and arduous struggle with COPD and helping her father navigate the healthcare system, she recognized that despite her many years of training, her work as a surgeon, and her leadership, she still wasn't doing the work that got her into medicine in the first place. She wanted to help people be healthy. Period.  That deep calling led her to become the Chief Operating Officer of The Vegan Gym, a global digital health platform dedicated to plant-based performance, healthspan, and longevity. She now hosts the Thrive on Plants podcast and is the Founder of The Longevity Lab. As a lifelong believer in equity and inclusion, Dr. Bascom works hard to ensure that this information is accessible to all people, and much of the education she puts together on these topics is available for free on her YouTube channel, @TheVeganGym.

Diana Johnson joined Tom Katz on Wake Up Tri-Counties for the "Here's to Your Health" series, discussing services at Hammond-Henry Hospital. Spotlighting local healthcare, Diana Johnson, a respiratory therapist with nearly two decades at Hammond Henry Hospital, discussed her pivotal role in the pulmonary function department. She performs pulmonary function tests, which help diagnose breathing issues like asthma, COPD, and chronic coughs, on patients ranging from age six to 100. Symptoms prompting referral include persistent shortness of breath or unexplained coughing, especially active during allergy season and for student athletes. The testing process is thorough, and results are reviewed promptly by a pulmonologist to guide further care. More about these services can be found at hammondhenry.com.

COPD can feel overwhelming when you are trying to memorize symptoms, diagnosis criteria, and treatment strategies all at once.      In this episode, Alex and I walk through a practical COPD review that covers the essentials you need to know for boards, including classic presentations, key differences between chronic bronchitis and emphysema, diagnostic spirometry cutoffs, and the GOLD treatment groups.                               Get full show notes, transcript, and more information here: https://blog.npreviews.com/COPD-review-for-boards              Follow us on Instagram: instagram.com/smnpreviewsofficial

While the gut microbiome often steals the spotlight, the microorganisms residing in our respiratory tract play a vital role in our health and immunity. In this episode, Dr. Sheena Fraser sits down with microbial ecologist Dr. Michael Cox to explore the fascinating, complex, and relatively uncharted territory of the lung microbiome.They discuss how the lung microbiome fundamentally differs from the gut, the daily flux of bacteria entering and leaving our airways, and the profound impacts of environmental factors like air pollution, smoking, vaping, and household cleaning products. Plus, Dr. Cox shares the massive challenges scientists face when studying these deep-tissue microbes and what the future of respiratory medicine might look like.What We Cover:From Seawater to Sputum: Using marine ecology techniques to decode human respiratory biology.Exploring the lungs' dynamic balance of microaspiration and mucociliary clearance.Meet the core lung bacteria (Streptococcus, Prevotella, Veillonella) and the puzzle of anaerobes in an oxygen-rich space.Environmental Disruptors: How pollution, smoking, and vaping inflame and alter the lung microbiome.Hidden Dangers of VOCs: The silent impact of everyday cleaning sprays and aerosols on respiratory health.Diet, Exercise, & Epigenetics: The systemic benefits of a high-fiber diet and fitness for chronic lung conditions like COPD and asthma.About Dr. Michael Cox is a microbial ecologist and the PGR Lead for the Institute of Microbiology and Infection at the University of Birmingham. His research focuses on the bacteria that reside in the respiratory tract in the context of respiratory diseases (such as COPD and Cystic Fibrosis). His lab works to understand the function of the respiratory microbiome, translate these findings for clinical benefit, and expand our understanding of the respiratory ecosystem beyond just bacteria.Connect with Dr Michael Cox:University of BirminghamScientific References & Further Reading:Cumming, K. J. (2018). "Long term effects of cleaning on the lungs." American Journal of Respiratory and Critical Care Medicine, 197(9):1099-1101.Hussain, S., et al. (2024). "Unlocking the secrets: VOCs and their devastating effects on lung cancer." Pathology - Research and Practice, 255:155157.Welsh, H. A., et al. (2026). "The effect of vaping on the human lung microbiota." Inhalation Toxicology, Vol 38, Iss 1.This podcast is brought to you in collaboration with the British Society of Lifestyle Medicine.Disclaimer:The content in this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your doctor or qualified healthcare provider. Never disregard professional medical advice or delay in seeking it because of something you have heard on this podcast.

Send us Fan MailMorning Prayer (Rejoice in LORD; Confess; Body of Christ; Diabetes; COPD; Mercy of God)Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peaceaimingforjesus.comYouTube Channel https://www.youtube.com/@aimingforjesus5346Instagram https://www.instagram.com/aiming_for_jesus/Threads https://www.threads.com/@aiming_for_jesusX https://x.com/AimingForJesusTik Tok https://www.tiktok.com/@aiming.for.jesus

Optimize patient outcomes by selecting the right inhaler device for the right patient. Credit available for this activity expires: 4/30/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/right-fit-personalizing-copd-device-selection-across-patient-2026a1000dcc?ecd=bdc_podcast_libsyn_mscpedu

As part of the April issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief Editor James Chalmers interviews Associate Editor Sanja Stanojevic about the joint statement from the Global Initiative for Chronic Obstructive Lung Disease and the Global Lung Function Initiative regarding the use of spirometry to define airflow obstruction and diagnose COPD, published in this issue of the ERJ (https://doi.org/10.1183/13993003.02574-2025). Cite this podcast as: ERJ Podcast April 2026: Use of spirometry to define airflow obstruction and diagnose COPD. Eur Respir J 2026; 67: 26E6704. [https://doi.org/10.1183/13993003.E6704-2026]

In this episode of Let's Talk Micro, we continue our gram-negative cocci series with a closer look at Moraxella catarrhalis—better known at the bench as the hockey puck bug. We break down what makes this organism unique, from its classic sliding colony morphology to how it behaves in different patient populations. Is it a colonizer or a pathogen? The answer depends on the clinical context. We walk through its role in pediatric infections like otitis media and sinusitis, its significance in adults—especially in COPD—and how to interpret its presence in respiratory cultures. As always, we tie it back to the bench, discussing identification clues, culture considerations, and what it means when you see this organism on your plate. Stay connected with Let's Talk Micro: Website: letstalkmicro.com Questions or feedback? Email me at letstalkmicro@outlook.com Interested in being a guest on Let's Talk Micro? Fill out the form here: https://forms.gle/V2fT3asjfyusmqyi8 Support the podcast: Venmo Buy me a Ko-fi  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to evolve rapidly with significant developments in drug approvals, regulatory changes, and innovative therapies. The latest updates highlight the tension between scientific advancement and regulatory scrutiny. A prime example is the FDA's proposal to rescind approval of Amgen's Tavneos due to alleged data manipulation and safety concerns. This action underscores the critical importance of rigorous data integrity and post-market surveillance in drug development. In a win for AstraZeneca, their Breztri Aerosphere has gained FDA approval for asthma treatment, strengthening its status as a blockbuster drug following its success in treating chronic obstructive pulmonary disease (COPD). This approval marks a significant milestone in AstraZeneca's ambition to achieve $80 billion in revenue by 2030. The inhaler's three-in-one formulation addresses a substantial unmet need in asthma management, offering enhanced convenience and efficacy for patients. Meanwhile, Novartis remains confident in its $5 billion peak sales projection for Pluvicto, even as it faces European regulatory setbacks and competitive pressures from bispecific antibodies. This scenario highlights the strategic resilience required by pharmaceutical companies to navigate regulatory landscapes and maintain market confidence amid challenges. Rocket Pharmaceuticals recently made headlines by selling a priority review voucher for $180 million following the approval of its gene therapy Kresladi. Such transactions are crucial for companies aiming to accelerate market entry for novel therapies, particularly in competitive fields like gene therapy. On the horizon for Kite Pharma, a subsidiary of Gilead Sciences, is the advancement of its next-generation CAR-T cell therapy for multiple myeloma. After refining its manufacturing processes, Kite is prepared to leverage its expertise in cell therapy to address the evolving landscape of hematologic malignancies. The potential approval of this therapy represents a significant step forward in personalized medicine and cancer treatment. GSK's ongoing legal dispute with AnaptysBio over Jemperli royalties emphasizes the complex interplay between strategic partnerships and intellectual property rights within the industry. As companies increasingly rely on collaborations for innovation, resolving such disputes amicably remains crucial for sustaining long-term alliances. Positive trial outcomes with Rezzayo from Mundipharma and CorMedix underscore an expanding focus on antifungal therapies, particularly for vulnerable populations like stem cell transplant recipients. This development could lead to broader prophylactic options against invasive fungal infections, improving patient outcomes in immunocompromised settings. Beyond therapeutic advancements, Medtronic's successful containment of a cyberattack highlights the growing importance of cybersecurity measures in safeguarding sensitive data and maintaining operational integrity. This incident reinforces the need for robust IT infrastructure within healthcare organizations to prevent disruptions and protect patient safety. Looking forward, Artificial Intelligence (AI) integration into pharma operations is reshaping traditional models from task execution to outcome ownership. AI-driven approaches are enabling life sciences organizations to scale impact, enhance decision-making processes, and accelerate value creation across drug discovery and development pipelines. Eli Lilly's collaboration with Profluent marks a significant move in the genetic medicine landscape. This $2.2 billion partnership focuses on developing AI-designed recombinases, a novel approach to gene editing that holds promise for addressing diseases with severe unmet needs. Recombinase-based Support the show

Chronic conditions like obesity, diabetes, COPD, and congestive heart failure are reshaping the U.S. healthcare system — and the demand for durable medical equipment along with it. In this episode of Industry Matters, VGM's Tyler Coulander and Alan Morris dig into the data behind America's growing chronic disease burden, what it means for DME providers navigating the shift from hospital-based to home-based care, and why demand for equipment and long-term patient support is more resilient than ever. They also tackle the big GLP-1 question: do drugs like Ozempic threaten CPAP and diabetes equipment markets, or do they actually open new doors? Tune in for a high-level look at the forces driving industry growth — and check out the VGM Industry Insights library for a deeper dive into the data.Watch the video version on YouTube: https://youtu.be/rwZAg90E3d8

Send us Fan MailPulmonologist Dr. Mitchell Rothstein shares his expertise on chronic obstructive pulmonary disorder, COPD. He explains what the condition is, how it manifests in the body, and the risks of untreated COPD. Dr. Rothstein also reviews available mainstream COPD medications and explains that even with the best medications, a failure in delivery can lower effectiveness. Dr. Rothstein also talks about the role inflammation can play for some people with COPD and discusses new biologic medications that may help lower the burden for many COPD sufferers.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore some of the pivotal shifts and breakthroughs shaping the industry and their implications for drug development and patient care. In oncology, Merck & Co.'s Welireg triplet therapy faced a setback in its Phase 3 trial for first-line treatment of kidney cancer. Despite previous successes, this outcome underscores the complexity of developing oncology treatments and illustrates the ongoing need for innovative approaches to meet diverse patient needs. Meanwhile, Roche has reported promising results for Enspryng in its Phase 3 trial, demonstrating a 68% reduction in relapse risk for a rare neuroinflammatory disorder. This success highlights Roche's commitment to addressing unmet needs in rare diseases and paves the way for potential FDA approval. AstraZeneca continues to advance with Ultomiris, which showed significant results in reducing protein levels in urine for IgA nephropathy patients. This success not only expands Ultomiris' indications but also underscores AstraZeneca's focus on rare diseases, positioning them as leaders in this specialized market. Additionally, AstraZeneca's Tozorakimab met primary endpoints in COPD trials, showcasing new possibilities for managing this prevalent respiratory disease. On another front, Zai Lab's strategic evolution from licensing major pharma drugs to developing its own pipeline marks a significant maturation of China's biotech capabilities. This reflects a broader trend of Chinese firms seeking global footprints while navigating regulatory challenges to gain international credibility. Regulatory and strategic news also has its highlights: Pfizer is undergoing changes as its Chief Strategy and Innovation Officer steps down, possibly signaling a shift in strategic direction. Replimune's drastic workforce reduction following an FDA rejection exemplifies the harsh realities biotech companies face in regulatory pathways. Meanwhile, Gilead's retraction from a collaboration with Arcus Biosciences after a Phase 3 failure underscores the risks associated with antibody-based therapies. In other collaborations, Roche's Foundation Medicine is deepening ties with Bristol Myers Squibb to develop new diagnostic targets, illustrating how partnerships can drive innovation by leveraging combined expertise. In industry trends, there's a growing integration of medical affairs with commercial operations to optimize scientific exchange and product launches—this alignment is critical for ensuring new therapies reach patients efficiently. Eli Lilly's acquisition of Kelonia Therapeutics for up to $7 billion signals an increased focus on in vivo CAR-T capabilities. This acquisition could streamline cancer treatments by engineering T-cells directly within patients' bodies, offering potentially more effective therapeutic approaches. Globally, Biogen has expanded its partnership with TJ Biopharma for Felzartamab rights in China, reflecting strategic moves to penetrate Asian markets. GSK's Blenrep received Chinese approval for treating multiple myeloma, marking a significant advancement with this antibody-drug conjugate targeting BCMA. In Canada, ClearPoint Neuro gained approval for its neuro navigation system, highlighting precision medicine's role in enhancing therapeutic outcomes. The technological landscape is also evolving with Serif pioneering DNA-based therapeutics. Supported by Flagship Pioneering's $50 million investment, these innovations could revolutionize personalized medicine by offering tailored solutions. Ray Therapeutics' $125 million funding advancement in gene therapy candidates targeting retinal degeneration further underscores interest in genetic therapies as viable treatment options. In regulatory landscapes, there's a push for designing neurodegenerative trials that Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal advancements and strategic moves that are reshaping the landscape of drug development and patient care. In vaccine development, Sanofi has recently reported promising results from a comparative trial of its protein-based COVID-19 vaccine, Nuvaxovid, against Moderna's latest mRNA vaccine, MNEXspike. The focus here was primarily on tolerability, and Sanofi's candidate demonstrated a superior safety profile. This marks a significant moment in the ongoing evolution of vaccine technology, underscoring the importance of diversifying vaccine platforms to effectively address global public health challenges. Shifting to regulatory landscapes, the U.S. Food and Drug Administration has been tasked with expediting the review process for psychedelic drugs under a directive from former President Donald Trump. This move aims to enhance access to novel treatments for serious mental health conditions, reflecting a broader trend in medicine towards exploring therapeutic avenues beyond traditional pharmaceuticals. It highlights an increasing openness to alternative therapies that could potentially transform mental health care. Strategic acquisitions continue to fuel innovation within the sector. Eli Lilly's acquisition of Kelonia Therapeutics for up to $7 billion is particularly noteworthy. This investment marks Lilly's second venture into in vivo CAR-T technology this year, emphasizing its commitment to advancing cell-based therapies. Kelonia's work on phase 1-stage myeloma therapy showcases the potential of CAR-T modalities in treating complex diseases, promising expanded treatment options for patients. Globally, infrastructure development is gaining momentum with Biovac securing a $108 million finance package to establish Africa's first fully integrated vaccine production facility. This initiative is crucial for enhancing regional healthcare autonomy by addressing local health needs and reducing reliance on external supply chains—a step forward in building resilient healthcare systems. In oncology, Merck & Co. has unveiled clinical data for its PD-1xVEGF bispecific antibody in non-small cell lung cancer (NSCLC). The results reveal similar efficacy and safety profiles compared to existing treatments, suggesting promising prospects for this bispecific approach in oncology therapeutics. Bispecific antibodies are engineered to engage two different targets simultaneously, potentially enhancing anti-tumor efficacy by not only stimulating immune responses but also disrupting angiogenesis. This innovation represents a continued focus on targeted cancer therapies that enhance treatment precision. Similarly, AstraZeneca's IL-33 inhibitor has achieved another phase 3 success in treating chronic obstructive pulmonary disease (COPD). This reinforces the therapeutic potential of targeting interleukin pathways in inflammatory diseases and reflects AstraZeneca's strategic focus on respiratory conditions. Such successes highlight the promise of precision medicine in improving patient outcomes. On the topic of market expansion, GlaxoSmithKline's multiple myeloma treatment Blenrep has entered the Chinese market. This move exemplifies the growing importance of global market access strategies, ensuring that patients worldwide can benefit from cutting-edge therapies. Now let's turn our attention to some intriguing scientific developments. A former Genentech leader has launched a synthetic design lab focused on adaptive "smart" antibody-drug conjugates (ADCs) for cancer therapy. ADCs represent a significant leap forward in precision medicine by offering targeted cancer treatments that minimize damage to healthy cells. These "smart" ADCs could provide more effective and less toxic options for cancer patients. Support the show

Synopsis: This episode is proudly sponsored by Quartzy. At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Connect Biopharma, for a wide-ranging conversation on the future of asthma and COPD treatment. With over 30 years in pharmaceutical R&D and nine FDA-approved drugs to his name, Barry shares a rare insider perspective on building and scaling biotech companies—from pioneering HIV therapies that reshaped the AIDS epidemic to leading next-generation biologics targeting acute asthma exacerbations. He unpacks Connect's differentiated IL-4 receptor biology, the untapped opportunity in acute care settings, and why innovation has lagged for decades in treating exacerbations despite millions of ER visits annually. The conversation also explores the realities of running a publicly traded biotech in volatile markets, the evolving role of China in global drug discovery, and how leaders navigate geopolitical complexity while advancing science. As Connect approaches key clinical catalysts, this episode offers a compelling look at where biotech innovation, capital, and global strategy intersect. Biography: Dr. Barry Quart is the CEO of Connect Biopharma, (Nasdaq: CNTB), a clinical-stage company developing therapies for acute exacerbations of inflammatory diseases, such as asthma and COPD. Barry is currently leading the company's development of rademikibart, a best-in-class antibody that targets interleukin-4 receptor alpha (IL-4Rα) and reduces severe flare-ups called “exacerbations” that can occur with asthma and COPD and can lead to hospitalization and even death. Connect is the first company to enter this space addressing acute exacerbations of inflammatory diseases. Dr. Quart is a recognized industry leader with over 30 years of leadership experience and nine FDA-approved drugs under his belt. Barry brings deep expertise in drug development, biotech strategy, and bringing breakthrough therapies to the market. He holds a PharmD from the University of California, San Francisco.

In this episode of Docs in a Pod, hosts Dr. Rajay Seudath and Carmenn Miles sit down with Dr. Rodrigo Pereira for an informative and approachable conversation about Chronic Obstructive Pulmonary Disease (COPD). Together, they break down what COPD is, common causes and symptoms, and why early detection is so important. Docs in a Pod focuses on health issues affecting adults. Clinicians and other health partners discuss stories, topics and tips to help you live healthier. Docs in a Pod airs on Saturdays in the following cities:  7:00 to 7:30 am CT:  San Antonio (930 AM The Answer)  DFW (660 AM, 92.9 FM [Dallas], 95.5 FM [Arlington], 99.9 FM [Fort Worth])  6:30 to 7:00 pm CT: 

Gas cookers are a common feature in many kitchens, often preferred by chefs and home cooks for their precise temperature control but gas cookers emit a number of harmful substances when they are in use and even when they are off that can pollute the indoor air and harm your health. Nitrogen dioxide, or NO2, is a gas that is produced when natural gas is burned at high temperatures. It can damage your airways and worsen asthma and COPD. A recent report by the Dutch Lung Foundation found that gas cookers increased the risk of asthma in children by 42%. What are some other of these pollutants and their effects? And what can you do to reduce these risks? In under 3 minutes, we answer your questions! To listen to the last episodes, you can click here: ⁠⁠Is there any truth that lemon water is good for you ?⁠⁠ ⁠⁠Why do we get great ideas in the shower?⁠⁠ ⁠⁠Should I cut the electricity at home during a storm?⁠⁠ A podcast written and realised by Amber Minogue. First Broadcast: 2/11/2024 Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the Science of Skin Podcast, board-certified dermatologist Dr. Ted Lain sits down with world-renowned eczema and atopic dermatitis expert Dr. Peter Lio, founder of the Chicago Integrative Eczema Center, to unpack a game-changing shift in how dermatologists think about chronic inflammatory skin conditions. If you're a dermatologist, skincare professional, or someone managing eczema, psoriasis, seborrheic dermatitis, or other steroid-responsive skin conditions — this episode is essential listening. What you'll learn: Why topical corticosteroids, despite being effective, carry real risks with long-term use — including skin atrophy, growth suppression in children, HPA axis suppression, and the increasingly recognized phenomenon of topical steroid withdrawal (TSW) What PDE4 (phosphodiesterase 4) is, how it drives the inflammatory cascade in atopic dermatitis, and why targeting it is a "Goldilocks" approach to treatment The evolution of PDE4 inhibitor topical therapies, including roflumilast (Zoryve) — its origins as an oral COPD drug and its transformation into a highly effective topical for eczema, psoriasis, and seborrheic dermatitis The concept of "PDE4 inhibitor-responsive dermatoses" — a new framework introduced in Dr. Lio's JAAD publication that expands the clinical use of this drug class across a wide range of skin conditions, including rare and pediatric diseases with zero FDA-approved treatments The excellent safety profile of topical roflumilast, including what side effects to watch for and how to counsel patients Why dermatologists must continue championing innovation in topical therapies — not just biologics — to serve patients with mild-to-moderate disease Featured guest: Dr. Peter Lio, MD — Clinical Assistant Professor of Dermatology and Pediatrics, Northwestern University; Founder, Chicago Integrative Eczema Center; Global speaker, researcher, and consultant in atopic dermatitis and inflammatory skin disease. Sponsored by Arcutis Biotherapeutics, makers of roflumilast (Zoryve) topical foam and cream. This episode was recorded ahead of the 2026 AAD Annual Meeting. Link to Dr. Lio's JAAD publication on PDE4 inhibitor-responsive dermatoses. DISCLAIMER: This podcast is not intended to provide diagnosis, treatment, or medical advice. Content provided in this podcast is for educational purposes only. Please consult with a physician regarding any health-related diagnosis or treatment See omnystudio.com/listener for privacy information.

Respiratory crises in the field rarely fit textbook categories. JEMS Development Editor Mike Brown talks with Hamilton Medical's Jesse Carroll to separate Type 1 (hypoxemic) from Type 2 (hypercapnic) respiratory failure and recognize the mixed presentations clinicians actually see. They walk through practical cues (SpO2 trends vs end‑tidal CO2), common causes (CHF, COPD, obesity, neuromuscular weakness), and epidemiology: roughly 360,000 prehospital respiratory calls annually with 41% involving COPD and obesity rates rising from 32% to about 60% since 1988. Jesse explains why pressure, flow and volume, not oxygen alone, drive meaningful physiologic change, how device limitations (disposable CPAP, pneumatic and turbine systems) affect flow delivery, and when early noninvasive strategies can buy time or prevent intubation.

About Dr. Raj Dr Raj is a quadruple board certified physician and associate professor at the University of Southern California. He was a co-host on the TNT series Chasing the Cure with Ann Curry, a regular on the TV Show The Doctors for the past 7 seasons and has a weekly medical segment on ABC news Los Angeles. More from Dr. Raj ⁠⁠⁠⁠⁠The Dr. Raj Podcast⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠Dr. Raj on Twitter⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠Dr. Raj on Instagram⁠⁠⁠⁠⁠ Want more board review content? ⁠⁠⁠⁠⁠USMLE Step 1 Ad-Free Bundle⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠Crush Step 1⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠Step 2 Secrets⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠Beyond the Pearls⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠The Dr. Raj Podcast⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠Beyond the Pearls Premium⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠USMLE Step 3 Review⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠MedPrepTGo Step 1 Questions⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠MedPrepTGo Step 2 Questions⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory condition that nurses encounter frequently in both inpatient and outpatient settings. Effective pharmacologic management plays a major role in controlling symptoms, preventing exacerbations, and improving quality of life for patients living with COPD. In this episode, we'll review the key medication classes used to manage COPD and highlight practical clinical considerations nurses should know when caring for these patients. Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE!

Environmental and civil engineer, professional hair braider, public health scholar, and triple HBCU alumna, Nemmi Cole, PhD joins the show to discuss outdoor air quality, warehouses, and respiratory health in California's Inland Empire on the Four Degrees to the Streets Podcast.From 1980 to 2021 the number of warehouses and industrial buildings in the Inland Empire grew to 1 Billion Square Feet (1,000,000,000 SQ FT). Nearly 40% of all goods and products coming into the U.S travel on trucks through or sit in warehouses within San Bernardino and Riverside Counties. In 2024, the 5 most polluted cities in the entire nation were within the Inland Empire including Ontario and San Bernardino. Children and adults living in these communities have the highest rates of asthma, lung disease, and COPD in the State of California. Diesel trucks, industrial waste, truck idling, and output of industrial machinery contribute to chemicals in the air such as Sulfur Dioxide, Particulate Matter, Nitrogen Dioxide, and Volatile Organic Compounds. Our guest on the podcast is a native of San Bernardino so her work is personal. On the show Nemmi reminisces and laments the loss of parks and farmland in her community to industrial buildings and warehouses.After completing her PhD in Civil and Environmental Engineering at Florida A&M University, our guest Dr. Nemmi Cole returned home to join the Keck School of Medicine at the University of Southern California to study the impact of megawarehouses on children's respiratory health outcomes in San Bernardino and Riverside County. Jasmine and Nemmi bonded over their shared passion for how neighborhood design shapes our mental and physical health. Download the episode to hear the civil engineering, environmental science, urban planning, and real estate perspective on warehouses, asthma, diesel trucks, globalization, zoning, and mental health.Share this episode with a friend or family member who cares about their neighborhood!Thank you for listening! Read Nemmi Cole, Phd full bio:Dr. Nemmi Cole is a researcher, engineer, and entrepreneur whose work sits at the intersection of science and social impact. Growing up in San Bernardino, California, with roots in Houston, Texas, she was driven by a deep intellectual curiosity about the world around her. That curiosity took her to Florida A&M University, where she became a proud triple alumna, earning her Bachelor's, Master's, and Ph.D. in Civil and Environmental Engineering.Her professional background spans academia, state and federal government, and international research, including roles as a Florida Gubernatorial Fellow - Federal Affairs Fellow in Washington, D.C, and as a Regulatory Program Assistant with the Florida Department of Environmental Protection. Most recently, she completed a Postdoctoral Fellowship at the University of Southern California's Keck School of Medicine, where she led research focusing on the impact of the built environment on children's respiratory health outcomes.Off the clock, she has spent nearly 28 years running her business, Braids by Nemmi, where she treats hair as a sophisticated art form rooted in culture and care. As she steps into her next chapter as a future faculty member, her mission is to equip the next generation of engineers and STEM professionals with the knowledge and practical skills to translate their academic training into real-world impact.References:Kim C, Gharib C, Atamna H. Pediatric Asthma in the Inland Empire: Environmental Burden, Gaps in Preventive Care, and Unmet Needs. Children (Basel). 2025 Sep 4;12(9):1183. doi: 10.3390/children12091183. PMID: 41007048; PMCID: PMC12468150. https://pmc.ncbi.nlm.nih.gov/articles/PMC12468150/Andre Perry. Know Your Price: Valuing Black Lives and Property in America's Black Cities. https://bookshop.org/p/books/know-your-price-valuing-black-lives-and-property-in-america-s-black-cities-andre-m-perry/6d4a4eab6505ab10?ean=9780815737278&next=t&next=t%2CtRose Institute of State and Local Government. 2024 Inland Empire Outlook. https://roseinstitute.cmc.edu/research/inland-empire and https://roseinstitute.org/wp-content/uploads/2024/03/IEO_Spring_2024_IE_Warehouses.pdf

In this episode of the podcast, I speak with Dr. Shereen Nabhani-Gebara, Professor of Oncology and Pharmacy at Kingston University and a leader in the EU-funded MULTIPULM project. We discuss how digital health innovations have the potential to transform the care of chronic respiratory diseases such as asthma and COPD, particularly in low- and middle-income countries. The conversation explores the challenges of delayed diagnosis, fragmented healthcare systems, and the rising burden of multimorbidity. Dr. Nabhani-Gebara shares how integrated digital ecosystems, including AI-powered monitoring tools, remote care platforms, and patient-centered education, have the capacity to enable earlier detection, proactive management, and improved outcomes. The episode also examines the role of global collaboration, the importance of adapting solutions to local contexts, and how these innovations could be applied in regions like the Middle East. A must-listen for anyone interested in digital health, global medicine, and the future of patient-centered care.

EVEN MORE about this episode!Do evil spirits and curses really exist, or are fear and belief shaping our reality?Join Julie Ryan for live energy healing, intuitive medical scans, past-life insights, and spirit messages that challenge common spiritual myths. Julie explains why fear-based beliefs have been used throughout history to control people—and why, in her experience, dark entities and curses simply don't exist.Throughout the show, Julie works with callers from around the country, performing intuitive energy scans and real-time healings. She uncovers the energetic root of issues like heart palpitations, COPD, and long-standing energy field leaks, tracing one imbalance all the way back to a decades-old surgery. Viewers will also hear how mineral deficiencies can affect heart rhythm, why electrolytes and quality salt can provide quick relief, and how energetic healing can help restore balance to the body.The episode also dives into past-life influences and spirit communication. Julie identifies a past-life trauma from an 1837 storm that may still be impacting abundance today and delivers a lighthearted message from a caller's deceased father—who happily reports he's “with the puppies” in the spirit world. Along the way, Julie reminds viewers that our thoughts broadcast our intentions to the universe, shaping the reality we experience. If you're curious about energy healing, intuitive health insights, or how beliefs influence your life, this fascinating session offers both practical wisdom and spiritual perspective.Episode Chapters:(0:00:00) - Introduction and Angelic Attendant Training™ Scholarship(0:12:00) - Medical Scan for Dog with Poisoning Symptoms(0:16:00) - Debunking Evil Spirits and Addressing Child Abuse(0:26:00) - Heart Palpitations and Mineral Deficiency Healing(0:30:00) - Past Life Scan for Abundance Blockages(0:36:00) - COPD Healing and Energy Field Membrane Repair(0:48:00) - Spirit Message from Deceased Father(0:52:00) - Blood Transfusion Investigation and Curse Debunking➡️Subscribe to Ask Julie Ryan YouTube➡️Julie's Intuitive Trainings✏️Ask Julie a Question!

To have Dr. Morse answer a question, visit: https://drmorses.tv/ask/ All of Dr. Morse's and his son's websites under one roof: https://handcrafted.health/ Facebook Page: https://www.facebook.com/handcrafted.health 00:00:00 - Intro  00:01:39 - Chronic Fatigue Syndrome (CFS/ME) -  Kidney/Liver Failure - Edema - Fibromyalgia - Pyelonephritis 00:32:48 - Chronic Obstructive Pulmonary Disease (COPD) 00:57:28 - Xanthelasma 01:06:02 - Clubfoot - Update with Eye Pictures 01:22:21 - Adrenal Tumor - Update with Eye Pictures 01:40:33 - Throat Issues 02:16:24 - Benign Epididymal Cysts 00:01:39 - Chronic Fatigue Syndrome (CFS/ME) -  Kidney/Liver Failure - Edema - Fibromyalgia - Pyelonephritis I do struggle with fatigue, especially in the fall/winter time. 00:32:48 - Chronic Obstructive Pulmonary Disease (COPD) I've been told that my condition of Emphysema is not curable. 00:57:28 - Xanthelasma I started having fat deposits around my eyes about a year and a half ago. 01:06:02 - Clubfoot - Update with Eye Pictures  I was born in 1991 with a left clubfoot. 01:22:21 - Adrenal Tumor - Update with Eye Pictures I had epilepsy since childhood 5 years of age. 01:40:33 - Throat Issues I have a digestive gurgling sound in my throat. 02:16:24 - Benign Epididymal Cysts I have recently been diagnosed with a benign epididymal cyst (spermatocele).